Cyclacel Pharmaceuticals, Inc.
Translating cancer biology into medicines.
Dundee, United States
12 employees
Post-IPO Equity
Total: $157.54M
Biotechnology, Health Care +2
General Information
Dundee, United States
BounceWatch is an independent company data service, not affiliated with Cyclacel Pharmaceuticals, Inc.. To contact Cyclacel Pharmaceuticals, Inc., visit cyclacel.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Cyclacel Pharmaceuticals, Inc. compare?
A PDF of Cyclacel Pharmaceuticals, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Cyclacel Pharmaceuticals, Inc. soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Cyclacel Pharmaceuticals, Inc. on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biotechnology
About Cyclacel Pharmaceuticals, Inc.
Business keywords: Pharmaceuticals, Biopharmaceutical, Cancer Treatment, Cell Cycle Control, Oral Therapies, Tumor Suppressor Biology, Cell Biology, Mitosis Mechanism, Mitotic Kinases, P53 Protein, Cancer Research, Drug Development, Sir David Lane, Professor David Glover, London
Funding Rounds & Investors (13)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $8.00M | - |
|
30 Apr 2024 |
| Post IPO Equity | $1.30M | - |
|
22 Dec 2023 |
| Post IPO Equity | $14.50M | - |
|
12 Mar 2021 |
| Post IPO Equity | $20.00M | - |
|
21 Apr 2020 |
| Post IPO Equity | $15.20M | - |
|
25 Jul 2017 |
| Post IPO Equity | $10.00M | - |
|
10 Apr 2014 |
| Post IPO Equity | $3.04M | - |
|
01 May 2012 |
| Post IPO Equity | $15.20M | - |
|
21 Oct 2010 |
| Venture Round | £5.00M | 1 |
|
01 Jul 2005 |
| Series D | £21.30M | 10 |
|
29 Jan 2004 |
Cyclacel Pharmaceuticals, Inc. Alternatives & Competitors
View All Alternatives
We are a biopharmaceutical company committed to the discovery and development of mono- and combinati...
Pioneering novel therapies to address cancer and metabolic disorders by targeting essential cellular...
Leveraging our protein engineering platform to improve cytokine-based immunotherapies for the treatm...
FAQ About Cyclacel Pharmaceuticals, Inc.
Source: BounceWatch company record for Cyclacel Pharmaceuticals, Inc., https://bouncewatch.com/company/cyclacel-limited, updated 30 December 2024. When citing, please name BounceWatch and link this page.
